selonsertib setback expect think compani remain nash focus
invest summari reiter overweight lower
pt think investor expect low
readout selonsertib show fibrosi improv
although set read
increas caution failur speak gilead manag
ir cfo cso disappoint result remain commit
nash current futur asset remov nash model
believ news could increas chanc compani make
acquisit shift timelin sinc think gilead like delay
unless buy late-stag nash asset intercept ow oca readout
nash expect also remov sale model adjust
nash sale previous contribut
chang dcf
think limit data selonsertib increas
clinic risk head readout basi caution
previous data support move base patient
selonsertib simtuzumab patient selonsertib /- simtuzumab
patient simtuzumab recal simtuzumab antibodi
work nash effect serv control trial see fibrosi
benefit rel short order week small group patient
think less like work base read-through
increas greater oxid stress occur nash
previous thought might greater chanc work sinc
believ may activ patient speak
cso note degre up-regul may similar
patient
strateg think news especi stellar fail
make like compani could acquir asset nash space
manag note commit intensifi space sinc view
selonsertib backbon therapi think compani could look
backbon therapi gut-restrict fxr agonist
inhibitor remain develop atla would need start
studi asset atla arm look encourag could delay
timelin coupl year
young/ merl host kol nash call fri et dial-
confirm
disclosur section may found page
use probability-adjust dcf analysi valu gilead share assum discount rate
model revenu assum termin valu
risk overweight rate price target includ hiv gener competit risk
particularli gsk cover brand side slower less success biktarvi
launch expect slow car-t sale current competit emerg next-gen
car-t failur cell therapi modal grow drive stabil growth long term
late-stag pipelin failur particularli nash franchis filgotinib trial
clinic regulatori commerci risk prevent franchis contribut
million except ep
hiv hbv
royalti contract revenu
provis incom tax
net incom gilead non-
net incom non-control interest
net loss non-control interest
growth ep dilut
net incom
non- reconcili
million except ep
acquisit relat amort intang
acquisition-rel amort inventori mark-up
acquisit relat amort intang
non- incom expens
incom tax effect non-gaap adjust
tax non-gaaap adjust
cog total
 total
sg total
issuanc stock share buyback
chang work capit
present valu flow
npv
npv termin valu
tv
million except ep
growth total hcv
growth total hiv
japan broken
japan broken
epclusa japan
japan
million except ep
million except ep
filgotinib ra crohn
unadjust sale gilead
adjust sale gilead
year
po see filgotinib summari break-out
adjust sale gilead
gilead global biopharmaceut compani major base busi revenu base infecti diseas
pipelin evolv inflamm oncolog nash compani headquart foster citi california
